175 related articles for article (PubMed ID: 33437946)
1. Weight gain during pregnancy among women initiating dolutegravir in Botswana.
Caniglia EC; Shapiro R; Diseko M; Wylie BJ; Zera C; Davey S; Isaacson A; Mayondi G; Mabuta J; Luckett R; Makhema J; Mmalane M; Lockman S; Zash R
EClinicalMedicine; 2020 Dec; 29-30():100615. PubMed ID: 33437946
[TBL] [Abstract][Full Text] [Related]
2. Maternal weight and birth outcomes among women on antiretroviral treatment from conception in a birth surveillance study in Botswana.
Zash R; Caniglia EC; Diseko M; Mayondi G; Mabuta J; Luckett R; Hofmeyr GJ; Morroni C; Ramogola-Masire D; Williams PL; Zera C; Wylie BJ; Makhema J; Lockman S; Shapiro RL
J Int AIDS Soc; 2021 Jun; 24(6):e25763. PubMed ID: 34176240
[TBL] [Abstract][Full Text] [Related]
3. Mother-to-Child HIV Transmission With In Utero Dolutegravir vs. Efavirenz in Botswana.
Davey S; Ajibola G; Maswabi K; Sakoi M; Bennett K; Hughes MD; Isaacson A; Diseko M; Zash R; Batlang O; Moyo S; Lockman S; Lichterfeld M; Kuritzkes DR; Makhema J; Shapiro R
J Acquir Immune Defic Syndr; 2020 Jul; 84(3):235-241. PubMed ID: 32195745
[TBL] [Abstract][Full Text] [Related]
4. Gestational diabetes in women living with HIV in Botswana: lower rates with dolutegravir- than with efavirenz-based antiretroviral therapy.
Mmasa KN; Powis K; Sun S; Makhema J; Mmalane M; Kgole S; Masasa G; Moyo S; Gerschenson M; Mohammed T; Legbedze J; Abrams EJ; Kurland IJ; Geffner ME; Jao J
HIV Med; 2021 Sep; 22(8):715-722. PubMed ID: 34003565
[TBL] [Abstract][Full Text] [Related]
5. Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: A randomised trial (DolPHIN-1 study).
Waitt C; Orrell C; Walimbwa S; Singh Y; Kintu K; Simmons B; Kaboggoza J; Sihlangu M; Coombs JA; Malaba T; Byamugisha J; Amara A; Gini J; Else L; Heiburg C; Hodel EM; Reynolds H; Mehta U; Byakika-Kibwika P; Hill A; Myer L; Lamorde M; Khoo S
PLoS Med; 2019 Sep; 16(9):e1002895. PubMed ID: 31539371
[TBL] [Abstract][Full Text] [Related]
6. Risks and Benefits of Dolutegravir- and Efavirenz-Based Strategies for South African Women With HIV of Child-Bearing Potential: A Modeling Study.
Dugdale CM; Ciaranello AL; Bekker LG; Stern ME; Myer L; Wood R; Sax PE; Abrams EJ; Freedberg KA; Walensky RP
Ann Intern Med; 2019 May; 170(9):614-625. PubMed ID: 30934067
[TBL] [Abstract][Full Text] [Related]
7. Comparative safety of dolutegravir-based or efavirenz-based antiretroviral treatment started during pregnancy in Botswana: an observational study.
Zash R; Jacobson DL; Diseko M; Mayondi G; Mmalane M; Essex M; Gaolethe T; Petlo C; Lockman S; Holmes LB; Makhema J; Shapiro RL
Lancet Glob Health; 2018 Jul; 6(7):e804-e810. PubMed ID: 29880310
[TBL] [Abstract][Full Text] [Related]
8. Treatment Outcomes of Dolutegravir- Versus Efavirenz-Based Highly Active Antiretroviral Therapy Regimens Among Treatment-Naive People Living With HIV.
Mahale PR; Patel BS; Kasmani N
Cureus; 2023 Jun; 15(6):e40139. PubMed ID: 37435267
[TBL] [Abstract][Full Text] [Related]
9. The predicted risk of adverse pregnancy outcomes as a result of treatment-associated obesity in a hypothetical population receiving tenofovir alafenamide/emtricitabine/dolutegravir, tenofovir disoproxil fumarate/emtricitabine/dolutegravir or tenofovir disoproxil fumarate/emtricitabine/efavirenz.
Asif S; Baxevanidi E; Hill A; Venter WDF; Fairlie L; Masenya M; Serenata C; Sokhela S; Chandiwana N
AIDS; 2021 Dec; 35(Suppl 2):S117-S125. PubMed ID: 34261099
[TBL] [Abstract][Full Text] [Related]
10. Reassuring Birth Outcomes With Tenofovir/Emtricitabine/Efavirenz Used for Prevention of Mother-to-Child Transmission of HIV in Botswana.
Zash R; Souda S; Chen JY; Binda K; Dryden-Peterson S; Lockman S; Mmalane M; Makhema J; Essex M; Shapiro R
J Acquir Immune Defic Syndr; 2016 Apr; 71(4):428-36. PubMed ID: 26379069
[TBL] [Abstract][Full Text] [Related]
11. Cost-Effectiveness of Dolutegravir Compared With Efavirenz for Prevention of Perinatal Transmission in Women Presenting With HIV in Late Pregnancy in Uganda.
Nuwamanya E; Nassiwa SC; Kuznik A; Waitt C; Malaba T; Myer L; Colbers A; Read J; Wang D; Lamorde M
Value Health Reg Issues; 2024 Jun; 44():101017. PubMed ID: 38905817
[TBL] [Abstract][Full Text] [Related]
12. Unexpected interactions between dolutegravir and folate: randomized trial evidence from South Africa.
Chandiwana NC; Chersich M; Venter WDF; Akpomiemie G; Hill A; Simmons B; Lockman S; Serenata CM; Fairlie L; Moorhouse MA
AIDS; 2021 Feb; 35(2):205-211. PubMed ID: 33086234
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of dolutegravir vs. efavirenz-based combined antiretroviral therapies in HIV-infected treatment-naive patients in a Nigerian treatment centre.
Isah A; Chukwu PO; Abba A; Igboeli NU; Ebere A; Omotola OF; Alozie FA; Ekwunife OI; Adibe MO
Afr Health Sci; 2023 Mar; 23(1):157-169. PubMed ID: 37545946
[TBL] [Abstract][Full Text] [Related]
14. Immunological, Cognitive, and Psychiatric Outcomes After Initiating Efavirenz- and Dolutegravir-based Antiretroviral Therapy During Acute Human Immunodeficiency Virus Infection.
Chan P; Yoon B; Colby D; Kroon E; Sacdalan C; Sriplienchan S; Pinyakorn S; Ananworanich J; Valcour V; Vasan S; Hsu D; Phanuphak N; Paul R; Spudich S
Clin Infect Dis; 2023 Feb; 76(3):e718-e726. PubMed ID: 35687498
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of three antiretroviral therapy regimens started in pregnancy up to 50 weeks post partum: a multicentre, open-label, randomised, controlled, phase 3 trial.
Chinula L; Ziemba L; Brummel S; McCarthy K; Coletti A; Krotje C; Johnston B; Knowles K; Moyo S; Stranix-Chibanda L; Hoffman R; Sax PE; Stringer J; Chakhtoura N; Jean-Philippe P; Korutaro V; Cassim H; Fairlie L; Masheto G; Boyce C; Frenkel LM; Amico KR; Purdue L; Shapiro R; Mmbaga BT; Patel F; van Wyk J; Rooney JF; Currier JS; Lockman S;
Lancet HIV; 2023 Jun; 10(6):e363-e374. PubMed ID: 37167996
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness and Safety of Dolutegravir Versus Efavirenz-Based Antiviral Regimen in People Living With HIV-1 in Sichuan Province of China: A Real-World Study.
Tongtong Y; Shenghua H; Yin W; Lin C; Huanxia L; Chunrong L; Ruifeng Z; Xiaojing Y; Yuan Y; Yuanhong H; Ke Y
J Acquir Immune Defic Syndr; 2022 Oct; 91(S1):S1-S7. PubMed ID: 36094508
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trial.
Lockman S; Brummel SS; Ziemba L; Stranix-Chibanda L; McCarthy K; Coletti A; Jean-Philippe P; Johnston B; Krotje C; Fairlie L; Hoffman RM; Sax PE; Moyo S; Chakhtoura N; Stringer JS; Masheto G; Korutaro V; Cassim H; Mmbaga BT; João E; Hanley S; Purdue L; Holmes LB; Momper JD; Shapiro RL; Thoofer NK; Rooney JF; Frenkel LM; Amico KR; Chinula L; Currier J;
Lancet; 2021 Apr; 397(10281):1276-1292. PubMed ID: 33812487
[TBL] [Abstract][Full Text] [Related]
18. An indirect comparison of efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir and dolutegravir + abacavir/lamivudine.
Rogatto F; Bouee S; Jeanbat V; Piontkowsky D; Aragao F; Bosse M
J Int AIDS Soc; 2014; 17(4 Suppl 3):19779. PubMed ID: 25397523
[TBL] [Abstract][Full Text] [Related]
19. Comparative Safety and Changes in Immunologic and Virologic Parameters of Dolutegravir versus Efavirenz-Based Antiretroviral Therapies Among HIV Patients: A Retrospective Cohort Study.
Ayal MA; Berha AB
HIV AIDS (Auckl); 2023; 15():173-190. PubMed ID: 37139483
[TBL] [Abstract][Full Text] [Related]
20. Brief Report: Weight Gain in Persons With HIV Switched From Efavirenz-Based to Integrase Strand Transfer Inhibitor-Based Regimens.
Norwood J; Turner M; Bofill C; Rebeiro P; Shepherd B; Bebawy S; Hulgan T; Raffanti S; Haas DW; Sterling TR; Koethe JR
J Acquir Immune Defic Syndr; 2017 Dec; 76(5):527-531. PubMed ID: 28825943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
